IN8bio appoints Jeremy Graff, Ph.D. as Class I director

IN8BIO, INC.

Board expanded from six to seven directors; Graff appointed effective May 1, 2023, term expiring at 2025 annual meeting.
Graff currently serves as Chief Scientific Officer of IMV, Inc.; previously President/CSO of Biothera Pharmaceuticals and Chief Development Officer at HiberCell.
Graff will serve on Nominating & Corporate Governance Committee and chair the Science and Technology Committee.
Compensation follows standard non-employee director policy; company entered into standard indemnification agreement with Graff.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeremy Graff, Ph.D.

Class I director

INAB · IN8BIO, INC.

Effective: 2023-05-01
Filed: May 1, 2023, 7:59 PM ET

appointed Jeremy Graff, Ph.D., as a Class I director of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jeremy Graff, Ph.D. was appointed as Class I director at IN8BIO, INC..

Action: appointed
Role: Class I director

Exact text from the filing

appointed Jeremy Graff, Ph.D., as a Class I director of the Company

View on SEC.gov

IN8BIO, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-130432

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.